Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland
- PMID: 11836629
Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland
Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a basic 38-amino acid peptide, which acts through three main G protein-coupled VIP/PACAP receptor subtypes, called PAC1, VPAC1 and VPAC2. We have investigated the expression and function of PACAP and its receptors in the rat adrenal gland. Reverse transcription (RT)-polymerase chain reaction (PCR) and radioimmune assay (RIA) allowed the detection of PACAP expression as mRNA and protein exclusively in adrenal medulla (AM). RT-PCR and quantitative autoradiography, using [(125)I]PACAP and selective VIP/PACAP receptor ligands, demonstrated the expression of PAC1 only in AM, and VPAC1 and VPAC2 in both AM and zona glomerulosa (ZG), PACAP receptor expression being absent in zona fasciculata/reticularis (ZF/R). PACAP38 concentration-dependently increased aldosterone secretion from dispersed ZG cells and catecholamine secretion from AM tissue, the maximal effective concentration being 10(-7) M. ZF/R cells did not display any secretory response to PACAP38. Aldosterone response of ZG cells to 10(-7) M PACAP38 was unaffected by the PAC1-antagonist (A) PACAP(6-38), and significantly decreased by the VPAC1-A [Ac-His(1),D-Phe(2),Lys(15),Arg(16)]VIP(3-7) GRF(8-27)-NH(2). Catecholamine response of AM tissue to PACAP38 was reduced, but not abolished, by both PAC1-A and VPAC1-A. The VPAC2 agonist (ago) Ro25-1553 elicited sizeable secretory responses from both ZG cells and AM tissue. PACAP38 (10(-7) M) evoked a marked rise in cyclic-AMP (cAMP) and inositol-1,4,5-triphosphate (IP3) production by ZG cells and AM tissue. cAMP response of ZG cells was lowered by VPAC1-A, and that of AM tissue by both PAC1-A and VPAC1-A. IP3 response of ZG cells and AM tissue was unaffected by PAC1-A and decreased by VPAC1-A. VPAC2-ago did not affect cAMP release, but raised IP3 production by both ZG cells and AM tissue. Aldosterone response of ZG cells and catecholamine response of AM tissue to PACAP38 (10(-7) M) were reduced by the adenylate cyclase (AC) and phospholipase-C (PLC) inhibitors (I) SQ-22536 and U-73122, as well as by the protein kinase (PK)A-I H-89 and PKC-I calphostin-C. Conversely, the secretory responses of both ZG and AM preparations to VPAC2-ago were annulled by PLC-I, lowered by PKC-I, and unaffected by either AC-I or PKA-I. Collectively, our findings allow us to conclude that in the rat adrenals: i) PACAP biosynthesis exclusively occurs in the AM; ii) ZG cells are provided with functional VPAC1 and VPAC2 receptors, whose activation by PACAP evokes a moderate aldosterone response; iii) AM cells possess all the subtypes of VIP/PACAP receptors, whose activation by PACAP elicits a marked catecholamine response; and iv) PAC1 receptors are coupled to the AC-dependent cascade, VPAC1 receptors to both the AC- and PLC-dependent cascades, and VPAC2 receptors exclusively to the PLC-dependent cascade.
Similar articles
-
Expression and function of vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and their receptors in the human adrenal gland.J Clin Endocrinol Metab. 2002 Jun;87(6):2575-80. doi: 10.1210/jcem.87.6.8571. J Clin Endocrinol Metab. 2002. PMID: 12050216
-
Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development.J Comp Neurol. 2000 Oct 2;425(4):495-509. J Comp Neurol. 2000. PMID: 10975876
-
Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.Cancer Res. 2000 Jun 1;60(11):3105-12. Cancer Res. 2000. PMID: 10850463
-
Endogenous ligands of PACAP/VIP receptors in the autocrine-paracrine regulation of the adrenal gland.Int Rev Cytol. 2006;249:1-51. doi: 10.1016/S0074-7696(06)49001-X. Int Rev Cytol. 2006. PMID: 16697281 Review.
-
Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors in the brain.Kaibogaku Zasshi. 2000 Dec;75(6):487-507. Kaibogaku Zasshi. 2000. PMID: 11197592 Review.
Cited by
-
PACAP-PAC1 Receptor Activation Is Necessary for the Sympathetic Response to Acute Intermittent Hypoxia.Front Neurosci. 2019 Aug 21;13:881. doi: 10.3389/fnins.2019.00881. eCollection 2019. Front Neurosci. 2019. PMID: 31496933 Free PMC article.
-
PACAP regulates immediate catecholamine release from adrenal chromaffin cells in an activity-dependent manner through a protein kinase C-dependent pathway.J Neurochem. 2009 Aug;110(4):1214-25. doi: 10.1111/j.1471-4159.2009.06206.x. Epub 2009 Jun 5. J Neurochem. 2009. PMID: 19508428 Free PMC article.
-
Pituitary Adenylate Cyclase-Activating Polypeptide: A Promising Neuroprotective Peptide in Stroke.Aging Dis. 2020 Dec 1;11(6):1496-1512. doi: 10.14336/AD.2020.0626. eCollection 2020 Dec. Aging Dis. 2020. PMID: 33269103 Free PMC article. Review.
-
Pituitary Adenylate Cyclase Activating Peptide and Post-traumatic Stress Disorder: From Bench to Bedside.Front Psychiatry. 2022 Jul 5;13:861606. doi: 10.3389/fpsyt.2022.861606. eCollection 2022. Front Psychiatry. 2022. PMID: 35865299 Free PMC article. Review.
-
PAC1 receptor antagonism in the bed nucleus of the stria terminalis (BNST) attenuates the endocrine and behavioral consequences of chronic stress.Psychoneuroendocrinology. 2014 Sep;47:151-65. doi: 10.1016/j.psyneuen.2014.05.014. Epub 2014 May 27. Psychoneuroendocrinology. 2014. PMID: 25001965 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources